Erbitux 500mg Infusion
Marketer
Merck Ltd
Salt Composition
Cetuximab (500mg)
Overview Erbitux 500mg Infusion
Cetuximab 500mg infusion is indicated for treating head and neck cancers and colorectal cancers. Its mechanism involves targeting cancer cells for elimination by the patient's immune system. Administration is intravenous, solely under a physician's direct supervision. Dosage and frequency are individualized, determined by your specific condition and subject to adjustment. Strict adherence to your physician's instructions is crucial; improper use or overdose can lead to severe adverse reactions. Discontinuation should only occur under medical guidance. Frequently reported side effects include nausea, headache, emesis, and skin eruptions. Report any concerning symptoms to your doctor; management strategies may be available. Immediately report sudden respiratory distress, dyspnea, pyrexia, or rigors. Routine blood monitoring of hematologic parameters, cardiac function, hepatic function, and electrolytes is mandatory. Increased sun sensitivity is a known effect; appropriate sun protection is advised. Prior to commencing therapy, disclose any pre-existing cardiac or renal conditions, or the use of anti-infectives. Significant drug interactions are possible; a complete medication list should be provided to your healthcare provider. This medication is contraindicated during pregnancy and lactation. Reliable contraception for both partners is essential throughout treatment to prevent conception.
Uses of Erbitux 500mg Infusion
Cancers affecting the head and neck, or the colon and rectum.
Major Benefits of Erbitux 500mg Infusion:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Erbitux 500mg Infusion:
- Nausea
- Headache
- Vomiting
- Conjunctivitis
- Skin rash
- Diarrhea
- Infusion reaction
- Decreased magnesium level in blood
- Increased liver enzymes
How to use Erbitux 500mg Infusion:
This medication will be administered by your healthcare provider. Self-medication is not advised.
How Erbitux 500mg Infusion works:
Cetuximab 500mg infusion, a targeted monoclonal antibody, selectively attaches to cancer cell receptors, marking them for elimination by the patient's own immune response.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Erbitux 500mg infusion lacks established safety data. Physician consultation is advised.
PregnancyCONSULT YOUR DOCTOR
Cetuximab 500mg infusion may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the benefits against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of 500mg Erbitux infusions while breastfeeding is likely unsafe. Scant evidence from human studies indicates potential drug transfer via breast milk, posing a risk to the infant.
DrivingUNSAFE
Cetuximab 500mg infusion may impair driving ability due to potential adverse reactions.
KidneySAFE IF PRESCRIBED
Cetuximab 500mg infusion is likely safe for individuals with impaired renal function. Preliminary evidence indicates dose modification may not be necessary. Physician consultation is recommended.
LiverCONSULT YOUR DOCTOR
Data regarding the administration of 500mg Erbitux infusions to individuals with hepatic impairment is scarce. Physician consultation is recommended.
What if you forget to take Erbitux 500mg Infusion :
Should you forget a scheduled Erbitux 500mg infusion, contact your physician immediately.
Facts to Know About Erbitux 500mg Infusion
| Label | Value |
|---|---|
| Chemical Category | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Monoclonal antibody EGFR (ErbB1/HER1) inhibitors |
3,018 People bought this recently